Treatment of metastatic malignant melanoma with recombinant interferon alfa-2b

1987 ◽  
Vol 5 (S4) ◽  
Author(s):  
T. Dorval ◽  
T. Palangie ◽  
M. Jouve ◽  
E. Garcia-Giralt ◽  
E. Falcoff ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Malignant Melanoma ◽  
Interferon Alfa ◽  
Recombinant Interferon

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.

1991 ◽  
Vol 9 (8) ◽  
pp. 1403-1408 ◽  
Author(s):  
C I Falkson ◽  
G Falkson ◽  
H C Falkson
Keyword(s):  
Malignant Melanoma ◽  
Treatment Failure ◽  
Partial Remission ◽  
Performance Status ◽  
Objective Response ◽  
Metastatic Malignant Melanoma ◽  
Interferon Alfa ◽  
Time To Treatment Failure ◽  
Metastatic Sites

Sixty-four patients with histologically confirmed metastatic malignant melanoma were entered on a prospectively controlled randomized trial. Patients received dacarbazine (DTIC) alone or DTIC plus interferon (IFN) alfa-2b. Patients were reasonably balanced with respect to age, sex, performance status (PS), site of metastases, and number of metastatic sites. Objective response (complete plus partial remission [CR + PR]) was documented in six patients on DTIC and in 16 patients on DTIC plus IFN alfa-2b. Median time to treatment failure (TTF) and median survival are significantly better on the combination arm, with some long-term CRs observed. More toxicity was encountered in the combination arm, which was acceptable except in three patients where treatment was discontinued because of IFN toxicity.

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.

1995 ◽  
Vol 13 (11) ◽  
pp. 2776-2783 ◽  
Author(s):  
E T Creagan ◽  
R J Dalton ◽  
D L Ahmann ◽  
S H Jung ◽  
R F Morton ◽  
...  
Keyword(s):  
Treatment Group ◽  
High Risk ◽  
Malignant Melanoma ◽  
Group Versus ◽  
Interferon Alfa ◽  
Stage I ◽  
Stage Ii ◽  
Control Group ◽  
Recombinant Interferon ◽  
Ifn Alpha

PURPOSE We conducted a randomized prospective trial in selected patients with fully resected high-risk stage I and II malignant melanoma. PATIENTS AND METHODS Interferon alfa-2a (IFN-alpha 2a) 20 x 10(6) U/m2 was administered three times each week for 12 weeks by the intramuscular route. Both the treatment group (n = 131) and the control group (n = 131) were evenly balanced with regard to relevant prognostic discriminants. RESULTS The median disease-free survival (DFS) time was 2.4 years for the IFN-alpha 2a group and 2.0 years for the observation group (log-rank P = 0.19). The median survival times were 6.6 years for IFN-alpha 2a and 5.0 years for observation (log-rank P = .40). For stage I patients (n = 102), there was no apparent therapeutic advantage from IFN-alpha 2a therapy. The DFS for stage II patients was a median of 10.8 months in the control group versus 17 months in the treatment group. The overall survival time was 4.1 years for the treatment group versus 2.7 years for the control group. The differences in DFS for stage II patient were significant in a Cox model. These results must be interpreted cautiously because of subset analysis. A severe flu-like toxicity occurred in 44% of patients, 13% lost at least 10% of their baseline weight, and 45% experienced a worsening of Eastern Cooperative Oncology Group (ECOG) performance score. CONCLUSION Our findings indicate trends that suggest a possible benefit for selected patients with high-risk malignant melanoma. The results will require further study in a larger patient population for confirmation.

Treatment of Metastatic Malignant Melanoma with Recombinant Interferon Alpha 2

Immunobiology ◽  
1986 ◽  
Vol 172 (3-5) ◽  
pp. 275-282 ◽  
Author(s):  
W.A. Robinson ◽  
T.I. Mughal ◽  
M.R. Thomas ◽  
Melinda Johnson ◽  
R.J. Spiegel
Keyword(s):  
Malignant Melanoma ◽  
Interferon Alpha ◽  
Metastatic Malignant Melanoma ◽  
Recombinant Interferon ◽  
Recombinant Interferon Alpha

Three consecutive phase II studies of recombinant interferon alfa–2a in advanced malignant melanoma. Updated analyses

Cancer ◽  
1987 ◽  
Vol 59 (S3) ◽  
pp. 638-646 ◽  
Author(s):  
Edward T. Creagan ◽  
David L. Ahmann ◽  
Stephen Frytak ◽  
Harry J. Long ◽  
M. N. Chang ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Phase Ii ◽  
Interferon Alfa ◽  
Recombinant Interferon ◽  
Phase Ii Studies ◽  
Advanced Malignant Melanoma ◽  
Consecutive Phase

Sequential Treatment with Interferon and Chemotherapy of Metastatic Malignant Melanoma. Total Remission of Cutaneous and Visceral Metastasis, but not of Cerebral Metastasis

1987 ◽  
Vol 73 (1) ◽  
pp. 55-58 ◽  
Author(s):  
Efisio Sulis ◽  
Carlo Floris ◽  
Antonio Chessa ◽  
Alberto Desogus ◽  
Antonio Muggiano ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Malignant Melanoma ◽  
Cerebral Metastasis ◽  
Interferon Α ◽  
Complete Disappearance ◽  
Apparent Effect ◽  
Visceral Metastasis ◽  
Recombinant Interferon ◽  
Ifn Therapy ◽  
Total Remission

A woman 35 years of age suffering from cutaneous and visceral metastatic melanoma was treated with recombinant Interferon α 2b (rIFNα2b) subcutaneously 3 × 106 U/m2 3 times a week for 3 months with no apparent effect on the course of the illness. Two months after IFN therapy the patient developed cerebral metastasis. A cycle of carmustine, 100 mg/day for 3 days, was given, and complete disappearance of the cutaneous and visceral, but not of the cerebral manifestations was observed. Two consolidation cycles based on vincristine, dacarbazine and lomustine were then administered. The patient died 26 months after beginning treatment with IFN and 18 months after chemotherapy for the cerebral metastasis. No trace of tumor at the cutaneous or visceral level was found at autopsy.

Sign in / Sign up

Export Citation Format

Share Document